Hemostemix Grants Stock Options
Calgary, Alberta--(Newsfile Corp. - December 11, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company")...
Day: December 11, 2025
BetterLife Pharma Announces Engagement with Shanghai-Based YAFO Capital
Vancouver, British Columbia--(Newsfile Corp. - December 11, 2025) - BetterLife Pharma Inc. (CSE: BETR) (OTCQB: BETRF) (FSE: NPAU) ("BetterLife" or the "Company"), an...
CASI Pharmaceuticals Announces Up to $20 Million Convertible Note Financing
- Investment to Fund Phase 1 Study in Renal Allograft Antibody-Mediated Rejection (AMR) in China SOUTH SAN FRANCISCO, CALIFORNIA /...
The Emergency Center Arizona (TEA) Rebrands to Canyon State Emergency Partners (CSEP) to Reflect Local Dedication and Physician-Led Model
PHOENIX, ARIZONA / ACCESS Newswire / December 11, 2025 / The Emergency Center Arizona (TEA), one of the largest physician-led...
AIML Announces Engagement of Guerilla Capital for Communications and Investor Outreach Efforts
TORONTO, ON / ACCESS Newswire / December 11, 2025 / AI/ML Innovations Inc. (CSE:AIML) ("AIML" or the "Company") is pleased...
Zomedica Announces Collaboration with Prime Video as Assisi Loop(R) Products Appear in New Holiday Film Merv
The collaboration highlights Zomedica's commitment to expanding pet wellness education as Assisi Loop technology is featured in the highly anticipated...
Cadrenal Therapeutics Acquires VLX-1005, a First-in-Class Phase 2 12-LOX Inhibitor for Patients with Heparin-Induced Thrombocytopenia (HIT)
Novel first-in-class therapeutic targeting a key immune signaling pathway and the underlying cause of HITIt is the first and only potent,...
60 Degrees Pharmaceuticals Announces Expansion of ARAKODA® Sales and Marketing in 2026
6-month commercial pilot demonstrated increasing demand among prescribersExpansion plan includes doubling the number of sales reps, a new GoodRx partnership,...
Matisse Pharmaceuticals receives INN isupartob sodium recognizing first-in-class drug status for M6229
isupartob sodium product picture Product picture of isupatob sodium (formally known as M6229), which is a treatment in clinical development...
Geron Corporation Announces Strategic Restructuring Plan to Position the Company for Long-Term Value Creation
Restructuring Supports RYTELO® U.S. Commercial Strategy and Investment in Clinical Development Expected to Reduce 2026 Projected Operating Expenses FOSTER CITY,...
Praxis Precision Medicines Announces Plans to File an NDA for Relutrigine in SCN2A and SCN8A Developmental and Epileptic Encephalopathies in Early 2026
EMBOLD data to serve as basis of efficacy and safety following discussion with the FDABOSTON, Dec. 11, 2025 (GLOBE NEWSWIRE)...
NEXGEL Announces Spin-Off of Drug Delivery Program into NexGelRx
NEXGEL shareholders will receive a non-dilutive 19.99% equity interest in NexGelRx up to $8 million of capital investment in spin-off...
Aligos Therapeutics Presents Positive Data at HEP-DART 2025
Oral presentation of ALG-055009 in vivo nonclinical data showcases synergistic fat mass loss in combination with incretin receptor agonists SOUTH...
Bionano Recaps Advances in Optical Genome Mapping Showcased at AMP 2025
SAN DIEGO, Dec. 11, 2025 (GLOBE NEWSWIRE) -- Bionano Genomics (NASDAQ: BNGO) participated in the Association for Molecular Pathology (AMP)...
MAIA Leadership Continues Insider Buying in 2025 and Trial Data Signals Breakout Potential
CHICAGO, Dec. 11, 2025 (GLOBE NEWSWIRE) -- A recent round of open-market purchases marks another display of confidence as the...
ImmuneWalk Therapeutics Announces Positive Results from Phase 1 SAD/MAD Study of IW-601, a First-In-Class Therapeutic with Broad Potential in Inflammatory and Autoimmune Diseases
Phase 1 Clinical Trial Met All Primary and Secondary Endpoints and Demonstrated Positive Safety, Pharmacokinetics, and Mechanistic ValidationClinical Data Build...
Ophirex Announces Business Update: Advances Toward Food and Drug Administration (FDA) Approval for Varespladib as Novel Oral Snakebite Treatment
Company announces agreement with FDA on human approval pathway based on Animal Rule Varespladib has received FDA MUMS designation for...
Stryker declares an $0.88 per share quarterly dividend
Portage, Michigan, Dec. 11, 2025 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) announced that its Board of Directors has declared a quarterly...
ViroMissile Announces First-in-Human Phase I Trial of IDOV-Immune for Advanced Solid Tumors
Study examines the safety and early efficacy of an oncolytic virus via a single intravenous doseSAN DIEGO, Dec. 11, 2025...
PatchMD Launches New Dopamine Support Patch for Natural Mood and Focus Support
Original Vitamin Patch Pioneer Introduces Comprehensive Dopamine Precursor Formula Backed by Clinical ResearchLas Vegas, NV, Dec. 11, 2025 (GLOBE NEWSWIRE)...